| Enzo Biochem's Clinical Labs Unit Enters into Co-Marketing Program with MMF Systems, Inc., for Web-Based Medical Records and Practice Management Software (Business Wire) NEW YORK----Enzo Biochem, Inc., announced today that Enzo Clinical Labs, Inc., its reference lab division serving physicians and medical facilities in the New York metropolitan area, has entered into a trial co-marketing services agreement with privately-owned MMF Systems, Inc. , of New York City, involving MMF’S state of the art medical records system. us.rd.yahoo.com |
FDA Panel Backs Novartis MS Drug An FDA panel unanimously said a proposed Novartis drug that would treat multiple sclerosis was safe and effective. online.wsj.com |
Cord Blood America Says Two Recent Financial Transactions Strengthen Company's Balance Sheet (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has had positive movement on two financial obligations that further strengthen its balance sheet. us.rd.yahoo.com |
JOHNSON'S® Brand Launches JOHNSON'S® NATURAL™ Product Line for Babies and Kids - Video SKILLMAN, N.J., Aug. 26 /PRNewswire/ -- JOHNSON'S® Brand, the leading expert in baby skincare, introduces JOHNSON'S® NATURAL™, a line of products that naturally and gently care for baby's skin and hair featuring at least 98 percent plant and fruit-derived natural ingredients. The new line supports the needs of a growing number of moms looking for natural products as part of a natural lifestyle. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/johnsons/45901/ JOHNSON'S® NATURAL™ product line is formulated with a unique combina feedproxy.google.com |
Good News Keeps Coming for Amgen With Aranesp Vote EP Vantage submits:Amgen (AMGN) stands tall. A threat that a US expert panel would vote to tighten the use of its red blood cell booster Aranesp has faded away, another in a string of victories the world’s biggest biotech has scored in recent months to preserve its vital franchise in erythropoietin-stimulating agents (ESAs).While there is no doubt that safety concerns have undermined the California company’s stronghold, several regulatory and competitive threats have dissipated in recent months. As such, when an FDA advisory panel voted Monday to largely preserve the Aranesp label for chronic kidney disease (CKD) patients, Amgen investors and executives must have breathed a sigh of relief, as evidenced by a 2% rise in Amgen’s shares.Complete Story » seekingalpha.com |